Becton Dickinson completed the spin-off of its diabetes business, the companies announced on 1 April.
As announced in December, the new company is called Embecta Corporation, but will be commonly branded as embecta. The company's CEO is medtech veteran Dev Kurdikar, who was the worldwide president of BD’s diabetes business
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?